replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Company profile
Ticker
REPL
Exchange
Website
CEO
Robert Coffin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Replimune, Inc. • Replimune Limited • Replimune Securities Corporation • Replimune (Ireland) Limited ...
REPL stock data
Latest filings (excl ownership)
8-K
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
26 Mar 24
10-Q
2024 Q3
Quarterly report
8 Feb 24
8-K
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
8 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Other Events
5 Dec 23
10-Q
2024 Q2
Quarterly report
7 Nov 23
8-K
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
19 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
7 Sep 23
Latest ownership filings
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Apr 24
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Veleka Peeples-Dyer
3 Apr 24
4
Sushil Patel
3 Apr 24
4
Paolo Pucci
3 Apr 24
4
Konstantinos Xynos
3 Apr 24
4
Kapil Dhingra
3 Apr 24
4
Emily Luisa Hill
3 Apr 24
4
Christopher Sarchi
3 Apr 24
4
JOSEPH P SLATTERY
3 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 77.63 mm | 77.63 mm | 77.63 mm | 77.63 mm | 77.63 mm | 77.63 mm |
Cash burn (monthly) | 10.16 mm | 1.08 mm | 21.28 mm | 17.84 mm | 14.53 mm | 12.80 mm |
Cash used (since last report) | 67.55 mm | 7.16 mm | 141.43 mm | 118.60 mm | 96.58 mm | 85.06 mm |
Cash remaining | 10.09 mm | 70.47 mm | -63.80 mm | -40.96 mm | -18.95 mm | -7.43 mm |
Runway (months of cash) | 1.0 | 65.4 | -3.0 | -2.3 | -1.3 | -0.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 136 |
Opened positions | 13 |
Closed positions | 21 |
Increased positions | 51 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 931.11 bn |
Total shares | 63.13 mm |
Total puts | 1.30 mm |
Total calls | 1.99 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price | 5.79 mm | $98.95 bn |
Baker Bros. Advisors | 4.58 mm | $78.33 bn |
Redmile | 4.16 mm | $71.24 bn |
BLK Blackrock | 3.96 mm | $67.72 bn |
Omega Fund IV | 3.61 mm | $0.00 |
Omega Fund Management | 3.00 mm | $51.35 bn |
Vanguard | 2.60 mm | $44.42 bn |
STT State Street | 2.37 mm | $40.56 bn |
JHG Janus Henderson | 2.17 mm | $37.07 bn |
BVF | 2.14 mm | $36.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Levitsky Hyam | Stock Option Common Stock | Grant | Acquire A | No | No | 7.73 | 32,000 | 247.36 k | 32,000 |
1 Apr 24 | Andrew Schwendenman | Common Stock | Grant | Acquire A | No | No | 0 | 17,775 | 0.00 | 40,536 |
1 Apr 24 | Andrew Schwendenman | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.73 | 53,325 | 412.20 k | 53,325 |
1 Apr 24 | Konstantinos Xynos | Common Stock | Grant | Acquire A | No | No | 0 | 26,665 | 0.00 | 139,379 |
1 Apr 24 | Konstantinos Xynos | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.73 | 80,000 | 618.40 k | 80,000 |
1 Apr 24 | Dhingra Kapil | Stock Option Common Stock | Grant | Acquire A | No | No | 7.73 | 32,000 | 247.36 k | 32,000 |
1 Apr 24 | Pucci Paolo | Stock Option Common Stock | Grant | Acquire A | No | No | 7.73 | 32,000 | 247.36 k | 32,000 |
News
Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024
8 Apr 24
Replimune Group: Q3 Earnings Insights
8 Feb 24
Replimune Group Q3 EPS $(0.77) Beats $(0.93) Estimate
8 Feb 24
Press releases
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
7 Apr 24
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
26 Mar 24
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
6 Mar 24
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
8 Feb 24